Want to see IMCR full AI Analyst Report?
IMCR Stock Chart & Stats
$36.75
-$0.51(-1.44%)
At close: 4:00 PM EDT
$36.75
-$0.51(-1.44%)
Day’s Range― - ―
52-Week Range$27.50 - $40.71
Previous CloseN/A
Volume530.38K
Average Volume (3M)437.05K
Market Cap
$1.54B
Enterprise Value$1.17B
Total Cash (Recent Filing)$880.21M
Total Debt (Recent Filing)$434.96M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Nov 11, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding51,498,615
10 Day Avg. Volume505,489
30 Day Avg. Volume437,050
Financial Highlights & Ratios
PEG Ratio1.36
Price to Book (P/B)4.59
Price to Sales (P/S)5.87
P/FCF Ratio-156.07
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue2.91
Enterprise Value/Gross Profit2.94
Enterprise Value/Ebitda71.41
Forecast
1Y Price Target
$62.83Price Target Upside70.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.06
Revenue Forecast (FY)$452.25M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginsRapid revenue expansion alongside consistently exceptional gross margins indicates strong product-level economics and growing commercial adoption. Although profitability is not yet established, this scale and margin profile can support reinvestment in the pipeline and improve operating leverage over the next several quarters.
Pipeline Expansion Beyond OncologyBeginning clinical testing of IMC-S118AI in type 1 diabetes extends Immunocore’s TCR platform into a serious disease beyond its marketed cancer therapy. A broader development pipeline creates additional long-term opportunities and reduces dependence on a single therapeutic indication if clinical progress continues.
Phase 3 Melanoma Expansion OpportunityCompleting enrollment in a large randomized Phase 3 study advances a potential expansion of KIMMTRAK beyond uveal melanoma into previously treated advanced melanoma. A successful overall-survival result could materially broaden the addressable patient population and strengthen the product’s strategic position.
Bears Say
Persistent Net LossesThe company has not yet converted strong revenue growth and high gross margins into sustained profitability. Continued net losses limit internally generated capital, increase reliance on successful commercial execution, and leave earnings vulnerable if investment needs remain elevated while the pipeline develops.
Elevated LeverageElevated leverage combined with ongoing losses reduces financial flexibility and increases execution risk. Debt obligations can constrain capital allocation and make it harder to fund clinical development or absorb setbacks internally, particularly before the business reaches durable positive earnings and cash generation.
Renewed Cash BurnNegative operating and free cash flow show that Immunocore is not yet self-funding despite its commercial growth. Sustained cash burn may require additional financing before profitability and cash conversion stabilize, potentially limiting investment flexibility and increasing the consequences of execution delays.
Immunocore Holdings News
IMCR FAQ
What was Immunocore Holdings’s price range in the past 12 months?
Immunocore Holdings lowest stock price was $27.50 and its highest was $40.71 in the past 12 months.
What is Immunocore Holdings’s market cap?
Immunocore Holdings’s market cap is $1.54B.
When is Immunocore Holdings’s upcoming earnings report date?
Immunocore Holdings’s upcoming earnings report date is Nov 11, 2026 which is in 21 days.
How were Immunocore Holdings’s earnings last quarter?
Immunocore Holdings released its earnings results on Aug 06, 2026. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of $0.01 by -$0.03.
Is Immunocore Holdings overvalued?
According to Wall Street analysts Immunocore Holdings’s price is currently Undervalued.
Does Immunocore Holdings pay dividends?
Immunocore Holdings does not currently pay dividends.
What is Immunocore Holdings’s EPS estimate?
Immunocore Holdings’s EPS estimate is -0.12.
How many shares outstanding does Immunocore Holdings have?
Immunocore Holdings has 51,498,615 shares outstanding.
What happened to Immunocore Holdings’s price movement after its last earnings report?
Immunocore Holdings reported an EPS of -$0.02 in its last earnings report, missing expectations of $0.01. Following the earnings report the stock price went up 3.635%.
Which hedge fund is a major shareholder of Immunocore Holdings?
Currently, no hedge funds are holding shares in IMCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunocore Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$62.83 (70.98% Upside)
$62.83 (70.98% Upside)
Blogger Sentiment
Neutral
IMCR Sentiment 50%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 734.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.1%
Last 30 Days ▲ 13.8%
Last 30 Days ▲ 13.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.08%
12-Months-Change
Fundamentals
Return on Equity
-2.35%
Trailing 12-Months
Asset Growth
3.42%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Immunocore Holdings
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.
IMCR Company Deck
IMCR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong commercial execution for KIMTRAK (29% YoY revenue growth to $400M), broad global adoption (39 approvals, 30 launches), meaningful real-world survival and duration signals, a diversified pipeline anchored by three Phase 3 trials with near-term readouts, and a solid cash position (~$864M). Balanced against this are expected revenue-growth moderation in 2026, rising R&D investment, event-driven timing uncertainty for key OS trials, small early-stage cohorts (HIV), and competitive/operational risks tied to trial geography and evolving treatment options. Overall, the company presents momentum and optionality but with important clinical and timing risks that will be clarified by upcoming data readouts.View all IMCR earnings summariesIMCR Stock 12 Month Forecast
Average Price Target
$62.83
▲(70.98% Upside)
Technical Analysis
Ownership Overview
0.04% Insiders
26.74% Mutual Funds
0.16% Other Institutional Investors
71.57% Public Companies and
Individual Investors